BD expects to bring the system to market in early 2026.

BD (NYSE: BDX) announced today that the FDA granted 510(k) clearance for its EnCore EnCompass breast biopsy and tissue ...

Becton, Dickinson and Company BDX, popularly known as BD, recently announced the global commercial launch of BD Research Cloud 7.0, marking another step forward in its AI-driven life sciences strategy ...

Earlier this year, BD revealed its intent to split from its lifesciences and diagnostic solutions business to become a pure-play medical device company. On the surface, medtech analysts have largely ...

BD, a leading global medical technology company, and Frazier Healthcare Partners, a leading private equity firm focused exclusively on the healthcare sector, announced a definitive agreement for BD to ...

Becton, Dickinson and Company BDX, popularly known as BD, recently announced the expansion of its partnership with Ypsomed to ...

After racking up a string of acquisitions throughout 2022—including one of the medtech industry’s largest of the year in its $1.5 billion buyout of Parata Systems—BD has yet to make any major ...

As the market for GLP-1 injections continues to grow, BD aims to ride that wave by providing drugmakers with its prefilled syringes. Biologic medications—including those blockbusters for diabetes and ...

On February 5, 2025, Becton, Dickinson and Company (BD) announced plans to separate its Biosciences and Diagnostic Solutions business into an independent entity. The Biosciences and Diagnostic ...

Becton, Dickinson and Co. is increasing its U.S. manufacturing capacity for essential medical devices, including syringes, needles and IV catheters. As part of a $10 million investment in 2024, new ...